Abstract:Parkinson’s disease arises from the demise of dopaminergic neurons in the substantia nigra resulting from both environmental and hereditary factors. Drug interventions can solely delay disease progression, but cannot provide a cure. Therefore, cell replacement therapy may represent a promising treatment approach. Although the United States has already employed this technology, independent clinical and preclinical trials are mandatory for its inclusion in Russia. The iPSC technology enables the acquisition of personalized iPSC lines for each patient, nearly eradicating the immune response. While autologous cell therapy is theoretically ideal, the reprogramming of patient cells into iPSCs and subsequent differentiation for each patient incurs time and cost. Alternatively, differentiated derivatives of low immunogenic iPSCs, lacking HLA class I expression, can serve as a substitute. These cells evade the T-cell immune response, but other minor HLAs and cells from the innate immune system, like macrophages and NK cells, could still participate in the immune response’s development, although not as potent as in allogeneic transplantation. While these cell products don’t escape the immune response entirely, they lessen it significantly, potentially enabling the use of less severe immunosuppressive therapy. In this study, a protocol previously established in the cell biology laboratory was used to differentiate iPSCs lacking HLA class I expression and wild-type iPSCs into midbrain dopaminergic neuron precursors. A thorough analysis of the forerunners was performed and demonstrated appropriate patterning. The progenitors were then implanted into the brains of rats with 6-OHDA-induced Parkinsonism and followed for 6 months to compare their in vivo differentiation to standard differentiation in vitro. In addition, the systemic inflammatory response of the animals to the transplantation and the biodistribution of the injected cells were investigated. The literature inadequately addresses the question of which cells, other than dopaminergic neurons, differentiate during in vivo graft differentiation and potentially cause side effects in cell therapy. The literature suggests that only approximately 3% of transplanted cells differentiate into dopaminergic neurons, which is adequate to improve motor function in model animals. We found that a significant proportion of the progenitors differentiate into glial cells. The dynamics of maturation of transplanted neurons was evaluated. Thus, we approached preclinical testing of the cell product after having characterized in detail the dynamics of maturation and the composition of the graft. Comparison of in vivo and in vitro differentiation will allow evaluation of the quality of cellular material for transplantation.

Human stem cell transplantation for Parkinson’s disease: A systematic review of survival and maturation of progenitors derived from human embryonic or induced stem cells in Parkinsonian models

Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson's disease

Stem Cell Therapy for Parkinson's Disease

Efficacy and Efficacy-Influencing Factors of Stem Cell Transplantation on Patients with Parkinson’s Disease: a Systematic Review and Meta-Analysis

The fate of iPSCs-derived low immunogenic dopaminergic neuron precursors after transplantation into the striatum of rats with 6-OHDA-induced parkinsonism

A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson's disease

Advancing Parkinson's disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells

Overcoming Methodological Challenges for Advancing Stem Cell Therapies in Parkinson's Disease

Neural grafting for Parkinson's disease: challenges and prospects

Transplantation in Parkinson’s Disease

Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease

Human Autologous Ipsc-Derived Dopaminergic Progenitors Restore Motor Function in Parkinson's Disease Models.

Survival and maturation of human induced pluripotent stem cell-derived dopaminergic progenitors in the Parkinsonian rat brain is enhanced by transplantation in a neurotrophin-enriched hydrogel

Research progress of neural stem cells as a source of dopaminergic neurons for cell therapy in Parkinson's disease

Redefining Parkinson’s Disease Research Using Induced Pluripotent Stem Cells

Therapeutic application of stem cell technology toward the treatment of Parkinson's disease.

Stem Cell Therapy for the Treatment of Parkinson's Disease: What Promise Does it Hold?

Cell therapy for Parkinson’s disease with induced pluripotent stem cells

Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery

Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in Parkinsonian rats

Midbrain Neural Stem Cells Show Unique Cell Survival, Neuronal Commitment and Neurotrophic Properties with Therapeutic Potential for Parkinson?s Disease